Status:
COMPLETED
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-80 years
Phase:
PHASE3
Brief Summary
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given br...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of COPD.
- Exclusion criteria:
- Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD.
- Other inclusion and exclusion criteria will be evaluated at the first study visit.
Exclusion
Key Trial Info
Start Date :
January 28 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 25 2006
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00269087
Start Date
January 28 2005
End Date
October 25 2006
Last Update
February 1 2019
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Kodaira, Japan, 187-0002
2
GSK Investigational Site
Kyoto, Japan, 612-0026
3
GSK Investigational Site
Osaka, Japan, 596-8501
4
GSK Investigational Site
Tokyo, Japan, 164-0012